RE:RE:RE:RE:A halt could come anytime now-- I don't know if they will report data on 90 days after 2nd treatment of 1st set of 12 patients, but that would be coming up in February, if they report Given severe under treatment on 1st treatment, they may want to show what an optimized treatment does and that would speed up enrolment for the remaining patients if data is good. All IMO, but that's up to principal investigators.
enriquesuave wrote:
Taken from last Quarterly in October. Seems like 2nd animal model may be done very soon perhaps. Imo
"Transferrin significantly increases the resistance of TLD-1433, the lead drug candidate, to photobleaching (loss of PDC potency over time), Reactive Oxygen Species (“ROS”) production (ability to destroy cancer cells quickly and effectively), selective tumour uptake (destruction of cancer cells, while sparing healthy cells), anti-cancer efficacy (efficiency in cancer cell destruction) and decreasing systemic toxicity (damage to healthy cells and/or organs) of the PDC. This makes Rutherrin® (TLD-1433 +transferrin) attractive for systemic treatment of recurrent, deep seated and/or progressive cancers.
Rutherrin®, a systemic formulation of TLD-1433 suitable for intravenous (“IV”) injection is being investigated to be injected via IV into the body, with a mandate of “hunting” and “destroying” cancer cells; wherever, they may reside in the body. The Company has demonstrated the significant anti-cancer efficacy of Rutherrin®, when activated by laser light or radiation treatment across, numerous preclinical in-vitro (cell lines) and in-vivo (animal) models; including: GBM and NSCLC.
The Company is currently conducting non Good Laboratory Practice (“GLP”) toxicology studies with Rutherrin® to determine the maximum recommended human dose of Rutherrin®, when administered systemically into the human body, via IV injections. Theralase® has completed one animal model and is diligently working to complete the second animal model. If successful, Theralase® will commence GLP toxicology studies in 2Q2021 with an aim to commencing a Phase Ib clinical study in GBM and NSCLC in 4Q2021."
enriquesuave wrote:
We may also soon see 2nd Animal model data for GBM and NSCLC I guess using X-ray activation. The beauty is that TLD-1433 exhibits very little photo bleaching and is able to be activated multiple times in same treatment sessions maybe with a small time interval between each activation. This could allow for maximum efficacy IMO
skys1 wrote: Impala, Roswell or Dr Coombs would be a servious bullish occurance, but I don't think anything will happen until that CR% gets to 60%, but that will happen this year. Then we will see the HALT.